SC66

SC66 is a small molecule Akt inhibitor that disrupts the PI3K/Akt/mTOR signaling pathway, leading to inhibition of cancer cell proliferation, increased apoptosis, and sensitization to chemotherapeutic agents[1][2][3]. SC66 induces cytotoxicity in multiple cancer types, including ovarian, cervical, and hepatoma cells, by inhibiting Akt phosphorylation and downstream effectors (such as 4EBP1, p70S6 kinase), decreasing glucose uptake, and suppressing the expression of pro-survival and chemoresistance factors like COL11A1, TWIST1, and Mcl-1[1]. It also promotes Akt ubiquitination and demonstrates synergistic effects with drugs like cisplatin and paclitaxel in preclinical cancer models[1]. SC66 was originally developed at Dana-Farber/Harvard Cancer Center[2].

Other names

Akt Inhibitor XVIII